Treatment of pulmonary exacerbations in cystic fibrosis - could do better?

被引：4
|
作者：
Smyth, Alan [1 ]
机构：
[1] Univ Nottingham, Sch Med, Nottingham NG7 2RD, England
来源：
PAEDIATRIC RESPIRATORY REVIEWS | 2016年 / 20卷
关键词：
Cystic fibrosis; Pulmonary exacerbations; Symptom score; Microbiome; Adverse effects of antibiotics; ACUTE-RENAL-FAILURE; TOBRAMYCIN; UK;
D O I：
10.1016/j.prrv.2016.06.004
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
This article describes the nature and significance of pulmonary exacerbations in cystic fibrosis (CF). The effectiveness and safety of current exacerbation treatment are explored. The article concludes with a summary of clinical trials (completed and ongoing) which aim to improve the efficacy and safety of exacerbation treatment. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [31] Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations
    Scott, L. Keith
    Toner, Robert
    LUNG, 2017, 195 (04) : 397 - 401
  • [32] Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States
    Rubin, Jaime L.
    Thayer, Sarah
    Watkins, Angela
    Wagener, Jeffrey S.
    Hodgkins, Paul S.
    Schechter, Michael S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (04) : 667 - 674
  • [33] Risk factors associated with pulmonary exacerbations in pediatric patients with cystic fibrosis
    Lubovich, Silvina
    Zaragoza, Silvina
    Rodriguez, Viviana
    Buendia, Jefferson
    Camargo Vargas, Bethy
    Alchundia Moreira, Jessica
    Galanternik, Laura
    Ratto, Patricia
    Teper, Alejandro
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2019, 117 (05): : E466 - E471
  • [34] Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations
    L. Keith Scott
    Robert Toner
    Lung, 2017, 195 : 397 - 401
  • [35] Reproducibility of Spirometry During Cystic Fibrosis Pulmonary Exacerbations
    Sanders, Don B.
    Rosenfeld, Margaret
    Mayer-Hamblett, Nicole
    Stamey, David
    Redding, Gregory J.
    PEDIATRIC PULMONOLOGY, 2008, 43 (11) : 1142 - 1146
  • [36] Ventilatory Threshold and Risk of Pulmonary Exacerbations in Cystic Fibrosis
    Campos, Natalia E.
    Vendrusculo, Fernanda M.
    Perez-Ruiz, Margarita
    Donadio, Marcio V. F.
    RESPIRATORY CARE, 2023, 68 (05) : 620 - 627
  • [37] Vitamins a and e and pulmonary exacerbations in patients with cystic fibrosis
    Hakim, Fahed
    Kerem, Eitan
    Rivlin, Joseph
    Bentur, Lea
    Stankiewicz, Halina
    Bdolach-Abram, Tali
    Wischanski, Michael
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2007, 45 (03) : 347 - 353
  • [38] Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis
    Fireizen, Yaron
    Ahmed, Mohamoud
    Vigers, Timothy
    Akong, Kathryn
    Ryu, Julie
    Hahn, Andrea
    Fanous, Hani
    Koumbourlis, Anastassios
    Tirakitsoontorn, Pornchai
    Arrieta, Antonio
    Burgener, Elizabeth B.
    Koff, Jonathan
    Cogen, Jonathan D.
    Bouzek, Drake C.
    Hanley, Elin
    Keck, Allison
    Stout, Dayna
    Bradley, John
    Sagel, Scott D.
    PEDIATRIC PULMONOLOGY, 2025, 60 (03)
  • [39] Consideration of height-based tobramycin dosing regimens for the treatment of adult cystic fibrosis pulmonary exacerbations
    El Hassani, Mehdi
    Simard, Chantale
    Pilote, Sylvie
    Cloutier, Isabelle
    Soufsaf, Sara
    Marsot, Amelie
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (05) : 2246 - 2255
  • [40] Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: V. Aminoglycosides
    Young, David C.
    Zobell, Jeffery T.
    Stockmann, Chris
    Waters, C. Dustin
    Ampofo, Krow
    Sherwin, Catherine M. T.
    Spigarelli, Michael G.
    PEDIATRIC PULMONOLOGY, 2013, 48 (11) : 1047 - 1061
12345